INTRODUCTION
The CNS, as an immune privileged site, has evolved unique mechanisms to allow it to benefit from its resident myeloid cells, microglia, as well as from communication with the systemic immune system (Hanisch and Kettenmann, 2007; Louveau et al., 2015; Quan and Banks, 2007; Schlegelmilch et al., 2011; Schwartz and Shechter, 2010; Sierra et al., 2014; Tremblay et al., 2011; Ziv et al., 2006) . In the mouse embryo, microglia migrate from the yolk sac to the CNS at embryonic days 8-9, undergo a stepwise program of development that is synchronized with the brain developmental process, and subsequently acquire a stable phenotype essential for the brain protection and homeostasis (Ginhoux and Prinz, 2015; Matcovitch-Natan et al., 2016) . Microglia immune activity is restrained by dedicated immune inhibitory pathways that suppress unwanted inflammatory responses and tissue destruction that are often associated with immune activation (Hanisch and Kettenmann, 2007) . These checkpoint mechanisms include direct inhibitory interactions of microglia with neurons through the receptor-ligand pairs CX3CL1-CX3CR1 and CD200-CD200R, soluble molecules present in the CNS milieu (e.g., transforming growth factor b [TGF-b]), and intracellular regulators such as the transcription factor MafB (Butovsky et al., 2015; Kierdorf and Prinz, 2013; Lauro et al., 2015; Matcovitch-Natan et al., 2016; Ransohoff and Cardona, 2010) . Nevertheless, these mechanisms may be disadvantageous under extreme conditions when reparative microglial activity is needed.
Alzheimer's disease (AD) is an age-related neurodegenerative disease characterized by progressive memory decline and cognitive dysfunction, often manifested histologically by the parenchymal deposition of amyloid-beta (Ab) plaques, the formation of neurofibrillary tangles and neuroinflammation (Hardy and Selkoe, 2002; Holtzman et al., 2011) . Numerous studies reported conflicting results regarding the contribution of systemic immunity, recruited monocytes, and tissue-resident microglia to AD onset and disease progression (Baruch et al., 2016; Deardorff and Grossberg, 2017; Guillot-Sestier et al., 2015; Jay et al., 2015; Koronyo et al., 2015; Lai and McLaurin, 2012; Simard et al., 2006; Wang et al., 2016) . Some reports show that under such conditions, microglia acquire pro-inflammatory activity, which has been associated with disease escalation (Heppner et al., 2015; Tejera and Heneka, 2016; Wang et al., 2015; Yamasaki et al., 2014) . However, the current methods, analyzing bulk cell populations isolated based on a small set of surface markers, might be limited in resolving the heterogeneity, niche specificity, and complexity of immune cell types within the CNS (Elowitz et al., 2002; Geissmann et al., 2010; Hume, 2008) . Singlecell genomic technologies enable unbiased characterization of immune cell types and states, transitions from normal to disease and response to therapies, supporting comprehensive genomewide sampling by single-cell RNA sequencing (RNA-seq) as an effective tool to systematically resolve immune heterogeneity in AD (Deng et al., 2014; Grü n et al., 2015; Gury-BenAri et al., 2016; Jaitin et al., 2014; Junker and van Oudenaarden, 2014; La Manno et al., 2016; Mass et al., 2016; Matcovitch-Natan et al., 2016; Paul et al., 2015; Treutlein et al., 2014; Zeisel et al., 2015) . Single-cell analysis can further identify potential markers, pathways, and regulatory factors, promoting testable hypotheses to elucidate molecular mechanisms of immune regulation in AD (Jaitin et al., 2016; Matcovitch-Natan et al., 2016; Paul et al., 2015) . Taken together, it is still not clear whether microglial function in neurodegenerative diseases is beneficial but insufficient, or whether these cells are effective at early disease stages but lose their efficacy or even become detrimental later on. Importantly, the pathways and molecular mechanisms of microglia activity at the different stages of AD thereby remain controversial. Here, we combine massively parallel single-cell analysis with chromatin profiling, single-molecule FISH (smFISH), immunohistochemistry, genetic perturbation, and computational modeling to comprehensively characterize de novo the involvement of the immune system in AD progression. Using a mouse model of AD that expresses five human familial AD gene mutations (5XFAD), we uncover a disease-associated microglia (DAM) subtype. Further analysis identifies DAM in another mouse model of neurodegenerative disease, namely, amyotrophic lateral sclerosis (ALS). Our results also depict the pathways activated in DAM, which have been associated with known AD risk factors, but not specifically attributed to microglia. Using sub-tissue-focused single-cell RNA-seq and smFISH, we identified the spatial location of DAM in proximity to Ab plaques. Immunohistochemical staining showed an increased number of microglia that are positively stained for intracellular Ab particles and DAM-markers in both 5XFAD mice and in human AD postmortem brains. Comparing triggering receptor expressed on myeloid cells 2 (Trem2)
5XFAD with Trem2
+/+ 5XFAD mice revealed that initial DAM activation, that includes upregulation of Tyrobp, Apoe, and downregulation of microglia checkpoint genes (e.g., Cx3cr1 is Trem2-independent, but full activation of the DAM program including phagocytic and lipid metabolism activity is a consequential event that is Trem2-dependent. Overall, our study identifies a potential protective microglia type associated with neurodegeneration and outlines a general framework for studying the involvement of the immune system in AD pathology.
RESULTS
Identification of a Unique Microglia Type Associated with Alzheimer's Disease Current characterization of immune cells involved in AD has been obtained from populations sorted according to a small set of canonical cell-surface markers. Therefore, the observed gene expression signatures may obscure the presence of additional immune cell types and overlook the composite picture of related and dynamic subsets in the brain. To de novo characterize the immune cell types and states involved in AD, we first sorted all immune cells (CD45 + ) from brains of 5XFAD, a commonly used AD transgenic mouse model that expresses five human familial AD gene mutations (Oakley et al., 2006) , compared with ageand sex-matched wild-type controls, and performed massively parallel single-cell RNA-seq (MARS-seq) (Jaitin et al., 2014) (Figures 1A and S1A) . In order to link between the canonical surface markers to the genome-wide expression profiles, we used an index-sorting strategy that allowed for retrospective analysis of surface marker combinations of each individual cell (see the STAR Methods). Unsupervised graph-based clustering (PhenoGraph) (Levine et al., 2015) of all 8,016 single cells sorted from six wild-type and AD mice, created a detailed map of the ten most transcriptionally distinct subpopulations (Figures 1B and S1B; Table S1 ). These distinct immune subpopulations were based on cluster-specific expression patterns of the 500 most variable genes, allowing de novo identification of rare subpopulations. Our analysis identifies a monocyte state, represented in cluster V, a perivascular macrophage group in cluster IV (Zeisel et al., 2015) , several lymphocytes sub groups (B cells, T cells, natural killer [NK] cells; clusters VI-VIII), granulocytes (IX-X), and a large group of microglia cells (cluster I; Figures 1B and S1B) . Surprisingly, our analysis also identifies two small groups of cells, clusters II (4.2%) and III (2.8%), which displayed expression of microglial genes (Cst3 and Hexb) with an additional unique signature of lipid metabolism and phagocytic genes such as Apolipoprotein E (Apoe), lipoprotein lipase (Lpl), and Cystatin F (Cst7) (Figures 1B and S1B) .
Examining the contribution of wild-type versus AD backgrounds to each group of cells revealed a similar percentage of cells in perivascular macrophages, monocytes, group I (E) Volcano plot showing the fold change of genes (log2 scale) between DAM (microglia3) to homeostatic microglia (microglia1) from the AD male brain (x axis) and their significance (y axis, -loglog scale). See Table S2 . Highly significant genes are indicated by a red dot. p values were determined by Mann-Whitney U test with FDR correction. Individual female animals are shown in Figure S1D . See also Table S1 . microglia, granulocytes, and slight differences between the wildtype (WT) and the AD model in lymphocytes ( Figure 1C ). Strikingly, group II and III microglia represent distinctive microglia states observed in AD but not in the WT background, and we define this state as disease-associated microglia (DAM). Projection of the cells using t-distributed stochastic neighbor embedding (t-SNE), localizes the DAM group in proximity to the microglia territory and distinct from the monocytes and perivascular macrophages (Figures 1D and S1C ). Closer examination of the profiles and key marker genes of homeostatic microglia to group II and III DAM revealed similarity to the microglial program (e.g., Hexb and Cst3; Figures 1B, S1B, and S1C). However, DAM also demonstrate significant changes in gene expression compared with microglia such as reduction in the expression levels of several microglia homeostatic genes, including the purinergic receptors P2ry12/P2ry13, Cx3cr1, and Tmem119 (Figures 1B , 1E, and S1D) (Butovsky et al., 2015; Haynes et al., 2006; Hickman et al., 2013; Merino et al., 2016; Mildner et al., 2017) . Many more genes are upregulated in DAM including several known AD risk factors such as Apoe (Corder et al., 1993) , Ctsd (Paz-Y-Miñ o et al., 2015) , Lpl (Scacchi et al., 2004) , Tyrobp (Pottier et al., 2016) , and Trem2 (Guerreiro et al., 2013; Jonsson et al., 2013) (Figures 1E and S1D ; Table  S1 ). Comparison of homeostatic microglia to group II and III DAM shows that the expression changes for many of the DAM-specific genes are in the same trajectory but more pronounced in group III, which may suggest that group II is an intermediate state between homeostatic microglia and group III DAM ( Figures 1B and 1D ). Gene set enrichment analysis (GO) of DAMspecific genes revealed significant involvement (p < 1 3 10
À14
) in lysosomal/phagocytic pathways, endocytosis, and regulation of the immune response ( Figure S1E ).
Disease-Associated Microglia Dynamics during AD Progression AD is a progressive disease with gradual increase in neuronal death and loss of cognitive function (Ballard et al., 2011) . Identifying the relevant changes in DAM regulation along the course of the disease could shed light on the molecular mechanisms of DAM regulation and potentially suggest of new therapeutic targets. AD typically progresses in three general stages; earlystage, mild-moderate, and severe (Reitz and Mayeux, 2014) . In the 5XFAD AD model, these stages are accelerated: high levels of intraneuronal aggregated b-amyloid start to appear at around 1.5 months of age and amyloid and plaque deposition at 2-3 months of age. Neuronal loss and deficits in spatial learning initiate at around 6 months and severe cognitive dysfunction is observed at 7-8 months of age (Kimura and Ohno, 2009; Oakley et al., 2006) . We therefore performed single-cell RNA-seq in whole brains of 5XFAD mice at 1, 3, 6, and 8 months of age.
In order to enrich for the rare DAM cells over other immune populations, we used the single-cell data to identify potential markers. We identified CD9, Itgax (CD11c), Clec7a, and CD63 as potential DAM markers ( Figure 1E ; Table S2 ) and sorted 1,358 CD11c + microglia from the different time points along disease progression ( Figure S2A ure S2D ), which may limit biological relevance of bulk analysis using CD11c as a marker for AD (Chiu et al., 2013; Hickman et al., 2013; Holtman et al., 2015; Kamphuis et al., 2016; Landel et al., 2014; Orre et al., 2014a Orre et al., , 2014b Wang et al., 2015) . We therefore in silico removed all myeloid contaminants from the time course data and analyzed the remaining 893 DAM and microglial cells. To model the dynamics of microglia along disease progression we generated a k-nearest neighbors graph (kNN) of microglia cells from all major disease stages. Two-dimensional projection of the graph identifies homeostatic microglia and DAM on the two extremes of the graph with an intermediate group of cells connecting the two states ( Figure 2B ). This analysis demonstrated that microglia in the AD model, and not in the WT, display a transition from homeostatic microglia to DAM population as a function of disease progression (Figures 2B, 2C, and S2E) . While most genes do not change their expression as a function of microglia transition (Hexb), some genes display a decrease in gene expression along this activation axis (Cx3cr1) and some show an increase in their gene expression (Apoe, Lpl, CD9, Cst7, Trem2) ( Figure 2D ; Table S3 ). In order to define the temporal transcriptional changes leading to DAM formation, we generated a mathematical model based on a generalized logistic function to describe the temporal changes in gene expression ( Figure 2E ; see the STAR Methods). Our model depicts the molecular order of events in which microglia are switching from the homeostatic state to DAM ( Figure 2F ; Table S4 .
(G) Graphs showing the ordering of key marker genes along the transition axis. See also Figure S2 and Table S3 . Figure 1D , showing the spatial location of DAM in the cortex of AD mice (indicated by an arrow). Table S4 ). Analysis of genes in the different disease stages (Figure 2B) revealed that initial transition events are more frequent in earlier disease stages (3 months) and include downregulation of P2ry12/13 and Cx3cr1 and upregulation of Tyrobp and Apoe. Later regulatory events are more frequent in advanced stages of the disease (8 months) and include upregulation of Cst7, Lpl, and Trem2 ( Figures 2F and 2G ). Chromatin plays a major regulatory role in cell-type-specific functions and response . Transcriptional changes from latent enhancers, rather than previously established enhancers, could resolve whether the DAM program is an immediate transcriptional response or a less anticipated response that requires more complex chromatin rearrangements (Ostuni et al., 2013) . We therefore used a high sensitivity method for chromatin immunoprecipitation followed by sequencing (iChIP) comparing microglia and DAM enhancers in WT and AD mouse model (Lara-Astiaso et al., 2014). We observed a highly similar (r 2 = 0.86) global pattern of histone 3 lysine 4 di methyl regions (H3K4me2), which marks promoter and enhancer regions. Focusing on DAM-specific genes, we observed active H3K4me2 regions in both the microglia and DAM demonstrating that the DAM program is already primed in homeostatic microglia (Figures S2F and S2G) .
DAM Are Localized near AD Plaques
Our single-cell analyses were obtained from immune cells isolated from whole brains including the meninges and parenchyma of AD involved (e.g., cortex) and uninvolved (e.g., cerebellum) brain regions. In order to spatially orient the immune cell compositions within different brain regions, we repeated the single-cell sorting experiments on dissected cortex and cerebellum of 6-month-old AD and WT mice and compared the immune composition of these two regions using single-cell RNA-seq of all immune (CD45 + ) cells. Analyzing 6,347 cells from four AD and WT mice, we found that DAM are located within the cortex, but not the cerebellum of AD mice (Figures 3A, 3B, and S3A) . Using the rich molecular characteristics of DAM, we further performed immunohistochemistry staining and single molecule fluorescence in situ hybridization (smFISH). We focused on differentially expressed DAM markers and anti-Ab plaque labeling. Cortex staining for IBA-1, a classical homeostatic microglial marker, together with CD11c, shows a small overlap (6%) within WT mice. In contrast, we identified a significant population (22.3%) of microglia that co-expresses these markers in 6-month-old AD mice ( Figures 3C and 3D ). Examining the expression of IBA-1 positive with CD11c-positive cells in AD transgenic mice stained for Ab plaques shows that microglia co-express these markers in proximity to plaque foci ( Figure 3E ). Further, CD11c is co-expressed with TIMP2, a marker for DAM, on microglia cells in AD mice ( Figure S3B ). Probing for the spatial distribution of DAM-specific genes, Csf1 and Lpl, using smFISH, shows significant overlap of these two genes within microglia cells near the Ab plaques ( Figures 3F, 3G , S3C, and S3D). This attributes our identified DAM population to cells localized in the vicinity of the Ab plaques.
DAM Are Phagocytic Cells Conserved in Human and
Other Neurodegenerative Diseases DAM express high levels of phagocytic and lipid metabolism pathways. We therefore examined whether DAM would phenotypically show high incidence of intracellular phagocytic particles of Ab. We immunostained brain slices with Lpl, a DAM-specific gene previously identified as an AD risk factor, together with histological staining using Thioflavin-S, which labels both extracellular and intracellular forms of Ab (Rajamohamedsait and Sigurdsson, 2012) . Analysis of these brain slices show that microglia containing Thioflavin-S-labeled particles are mostly clustered in close vicinity of Ab plaques, from 1.8% of microglia in regions with low density of plaques to 60.6% in regions with high density of plaques ( Figures 4A and 4B ). These phagocytic microglia showed nearly complete co-expression of the DAM marker Lpl (95.8%; Figure 4B ). Further, in order to examine if DAM cells are conserved in human, we used the same strategy and stained human postmortem brains and age-matched non-AD controls for Ab and Lpl. Our analysis shows a very strong overlap between Lpl-positive microglia, predominantly around Ab plaques, in AD postmortem brain samples; such cells could not be detected in non-AD brain slices ( Figures 4C and S4A) .
To examine the presence of DAM in other neurodegenerative conditions, we performed single-cell analysis of all immune cells from spinal cords of a mouse model of ALS, a neurodegenerative disease characterized by the progressive degeneration of motor (legend continued on next page) neurons in the spinal cord (McCombe and Henderson, 2011) . We sorted 3,194 CD45 + cells from the spinal cords of mSOD1 (G93A) mice, a transgenic ALS mouse model mimicking the familial human disease (Gurney et al., 1994) , at early (day 80) and late (day 135) disease progression stages and performed single-cell RNAseq. Analysis revealed similar immune cell populations to those identified in the WT and AD mice with different proportions (Figures 4D and S4B ; Table S5 ). The majority of the cells were represented by microglia, expressing the relevant markers such as Hexb and Cx3cr1 ( Figures 4D, S4B , and S4C). Importantly, we also observed a distinct group of cells with microglia characteristics in the spinal cords of ALS mice but not in the WT mice ( Figures 4D and S4B ). These cells display an expression profile that is highly similar to the DAM observed in the AD model, including upregulation of Trem2, Tyrobp, Lpl, and Cst7 as well as downregulation of P2ry12 and Cx3cr1 (Figures 4E and S4B-S4D; Table S6 ). Of the total CD45 + cells, the percentage of DAM increases from 6% at day 80 to nearly 30% by day 135 (Figure 4F) , which points to further accumulation of DAM during ALS progression. To further generalize the regulation of DAM in various neurodegenerative conditions, we performed singlecell RNA-seq on 631 CD11b + immune cells isolated from whole brains of aged (20-month-old) mice compared with young (7-week-old) mice. Analysis of the microglia cells revealed a large increase of the DAM population in the aged mice compared with young adults, from non-detected to 3%, respectively (Figure S4E ). These results suggest that DAM actively participate in the dismantling and digestion of the amyloid plaques and are conserved from mouse to human neuropathology.
DAM Activation Is Initiated by a Trem2-Independent Mechanism
In order to better understand the regulatory mechanisms of DAM, we further analyzed the single-cell data, seeking potential regulators that may trigger DAM activation. Among them, we identified Tyrobp (Tyro protein tyrosine kinase binding protein) and Trem2 (triggering receptor expressed on myeloid cells 2), which form a signaling complex; both components are strongly induced in DAM ( Figure 1E ; Table S1 ) Painter et al., 2015; Wang et al., 2015) . Mutations in Trem2 were associated with risk factors in AD Guerreiro et al., 2013; Jonsson et al., 2013) and Trem2 deficiency in an AD mouse model accelerated Ab plaque accumulation and neuronal loss (Jay et al., 2015; Wang et al., 2015 Wang et al., , 2016 Yuan et al., 2016) . To decipher the role of Trem2 in DAM activation, we performed single-cell RNA-seq of DAM, using CD11c and CD11b enrichments, from whole brains of Trem2 +/+
5XFAD and Trem2
À/À 5XFAD mice together with matched WT and Trem2 À/À controls, altogether 3,864 cells.
Following digital sorting and removal of monocytes contaminants, the remaining microglia cells were clustered using a kNN graph and projected on a two-dimensional space, displaying a spectrum of transcriptional states from homeostatic microglia toward the DAM state ( Figure 5A ). Similar to our single-cell analysis of AD mice ( Figure 1B) , we observed three distinct microglia groups: homeostatic, intermediate state, and DAM ( Figure 5A) 5D , and S5). This analysis suggests that DAM are generated through a twostep mechanism of activation of homeostatic microglia ( Figure 6 ). An initial activation through an unknown mechanism leads to an intermediate state (stage 1) in a Trem2-independent mechanism, which critically involves reduction in the expression of homeostatic microglia checkpoint genes (e.g., Cx3cr1 and P2ry12/ P2ry13) and upregulation of genes such as B2m, Apoe (associated with AD progression) (Castellano et al., 2011) , and the Trem2 adaptor Tyrobp (Figures 5 and 6 ). This intermediate DAM program can be further activated by a secondary activation signal that is Trem2-dependent (stage 2) and involves upregulation of phagocytic and lipid metabolism genes such as Cst7 and Lpl (Figures 5 and 6 ). Interestingly, no cells with a Trem2-dependent program are observed without the Trem2-independent program, which suggests that DAM activation is a mechanistically coupled temporal event that must first be initiated in a Trem2-independent pathway, followed by activation of the Trem2-dependent program.
DISCUSSION
Immune cells and pathways are frequently implicated in neurodegenerative conditions. For the last decades, the nature of See also Figure S4 and Table S5 . (legend continued on next page) the involvement of microglia, as well as infiltrating immune cells, in the response to brain pathologies have been under constant debate (Chakrabarty et al., 2015; Guillot-Sestier et al., 2015) . This was partly due to technical limitations of using markerbased approaches analyzing heterogeneous cell populations, which made it difficult to accurately define the immune cell types and states involved in brain homeostasis and disease. As a result, various innate immune functions have been interchangeably attributed to either microglia or infiltrating blood-derived monocytes. For example, in AD, as in many other neurodegenerative diseases, the local neuroinflammation that is associated with cytotoxicity and disease escalation has often been attributed mainly to microglia (Mosher and Wyss-Coray, 2014; Prinz and Priller, 2014; Wang et al., 2015 Wang et al., , 2016 Yuan et al., 2016) . In contrast, several studies have attributed a positive role to infiltrating monocytes in the clearance of toxins from the brain (Baruch et al., 2015; Jay et al., 2015; Koronyo et al., 2015; Simard et al., 2006; Thé riault et al., 2015) .
In the current study, we were able to overcome many of these limitations, and avoid marker-based classifications, by using single-cell RNA sequencing for sampling single immune cells from the brain. Our work establishes a new experimental and conceptual paradigm to accurately analyze the involvement of the immune system in neurodegeneration and other brain pathologies. We identify a novel subtype of protective microglia, disease-associated microglia, DAM, and decipher their dynamics along the course of Alzheimer's disease progression. Using immunohistochemistry and smFISH, we found that DAM are spatially associated with sites of AD pathology. Closer examination of the genes expressed by DAM along disease progression revealed elevation of lipid metabolism pathways and phagocytic-related genes, corresponding to the need for plaque clearance in AD. Importantly, the DAM-specific program that we identify includes genes that encode a large number of known risk factors that contribute to disease mitigation. While they were previously identified in AD, they were not functionally linked with microglia. Among these genes is Lpl, whose mutations are associated with an aggressive form of AD (Baum et al., 1999) . Our study further shows that the expression of Lpl and additional risk factor genes occurs in the Trem2-dependent phase and attributes a new role for microglia function of these genes in AD. Immunostaining of DAM-specific genes together with Ab plaques identified enhanced phagocytic activity of DAM cells and their functional conservation in both mice and human AD brains. Single-cell genomic analysis of a large cohort of postmortem brains of AD patients with matched non-AD controls will enable to further identify the role of DAM in AD, and we suspect it will also point to a larger immune heterogeneity than observed in the mouse models.
Trem2 is a microglia-specific immunoreceptor, whose genetic variants are associated with increased risk of neurodegenerative diseases, and homozygous Trem2 loss of function mutations 
5XFAD (x axis) compared with the 5XFAD (y axis). (F) Comparison of log p values of the differential expression of stage 1 DAM versus homeostatic microglia in the Trem2
À/À 5XFAD (x axis) to the differential expression of stage 2 DAM versus homeostatic microglia in 5XFAD (y axis), log p values sign corresponds to upregulation or downregulation. See also Figure S5 and Table S7 . cause dementia in humans Hickman and El Khoury, 2014) . In addition, a rare variant of Trem2 has been associated with an increased risk for AD (Guerreiro et al., 2013; Jonsson et al., 2013; Song et al., 2017) . In addition to Trem2, we identify strong induction of Tyrobp in DAM. Tyrobp and Trem2 form a signaling complex, associated with Ab clearance, that could enhance phagocytic activity of microglia and participate in suppression of inflammatory responses by repression of microglia-mediated cytokine production and secretion (Ma et al., 2015) . Here, using Trem2 À/À 5XFAD mice, we were able to identify two sequential but distinct stages in DAM activation. The first step, which is Trem2-independent, involves activation of a set of genes, including the Trem2-signaling adaptor Tyrobp, Apoe, and B2m, concomitantly with downregulation of microglia homeostatic factors (e.g., Cx3cr1 and P2ry12/ P2ry13). The second phase of DAM activation, including induction of lipid metabolism and phagocytic pathways (e.g., Lpl, Cst7, and CD9), was found to be Trem2-dependent: this transition to fully activated DAM does not occur in the absence of the Trem2 receptor. The fact that expression of this set of genes is associated with phagocytic activity and lipid metabolism, and is dependent on Trem2, supports the recent observation that absence of Trem2 in microglia at the late stage of AD, but not at the early stage, exacerbates disease manifestations (Wang et al., 2015) . It is therefore possible that the function of the genes expressed by DAM is needed to mitigate the disease by supporting phagocytosis but it occurs at relatively late stage of the disease. Importantly, none of the genes expressed as part of the DAM program are the primary cause of the disease but rather affect AD timing of onset and rate of progression. Taken together, our results shed new light on the role of microglia in AD and suggest that at least a sub-population of microglia, the DAM, are beneficial for AD. It is possible that there is a tradeoff in brain homeostasis between the number of DAM cells with phagocytic activity and checkpoint mechanisms that keep them under tight control (e.g., CX3CR1 inhibitory signaling). Such checkpoint mechanisms, while essential for the function of microglia, for ensuring their risk-free immune activation, may become a negative factor when this balance is tilted and a strong phagocytic activity is needed in aging or under detrimental genetic backgrounds. In line with this hypothesis, is our current observation that the elevation of genes associated with the first step of DAM activation is tightly coupled with the loss of microglial homeostatic genes. Our results also support the observation that deficiency in CX3CR1 signaling in AD animal models, led to a reduction in Ab deposition (Lee et al., 2010) . It remains to be determined how targeting the microglia-specific inhibitory checkpoints can be used to induce early DAM activation and may be adopted as a therapeutic (or preventive) target to trigger a microglial response against AD plaque pathology, aging, and other neurodegenerative diseases.
Generalizing our study to other neurodegenerative diseases, we found a similar DAM subpopulation in an ALS mouse model. This suggests that DAM are not associated with the specific primary cause of disease pathology or disease etiology, but rather with a general program that is involved in clearance of the protease-resistant misfolded and aggregated proteins that commonly accumulate in neurodegenerative diseases and general aginginduced damage (Yerbury et al., 2016) . If this is the case, our study suggests that blocking microglia-specific checkpoints might provide a therapeutic approach to unleash the ability of resident microglia to combat neurodegenerative disorders.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by Lead Contact Ido Amit (ido.amit@ weizmann.ac.il).
EXPERIMENTAL MODEL AND SUBJECT DETAILS Animals
Heterozygous 5XFAD transgenic mice (on a C57/BL6-SJL background) that overexpress familial AD mutant forms of human APP (the Swedish mutation, K670N/M671L; the Florida mutation, I716V; and the London mutation, V717I) and PS1 (M146L/L286V) transgenes under the transcriptional control of the neuron-specific mouse Thy-1 promote (Oakley et al., 2006 ) (5XFAD line Tg6799; The Jackson Laboratory), and male Heterozygous mSOD1 G93A mice on a C57BL/6J background, were taken throughout adulthood in different time points as indicated in the text. Mice were bred and maintained by the animal breeding center of the Weizmann Institute of Science. All experiments detailed herein complied with the regulations formulated by the Institutional Animal Care and Use Committee (IACUC) of the Weizmann Institute of Science. For the Trem2 experiments, Trem2 À/À mice were generated as previously described (Turnbull et al., 2006) ; 5XFAD mice were purchased from the Jackson Laboratory (MMRRC) and crossed to Trem2 À/À mice to generate Trem2 +/À 5XFAD and Trem2 À/À 5XFAD mice. These mice were bred and housed in the Washington University animal house.
Paraffin embedded sections of human brains Human brain sections of postmortem Alzheimer's disease and non-CNS-disease aged matched individuals were obtained from the Oxford Brain Bank (formerly known as the Thomas Willis Oxford Brain Collection (TWOBC)) with appropriate consent and Ethics Committee approval (TW220). The experiments involving these sections were approved by the Weizmann Institute of Science Bioethics Committee.
METHOD DETAILS
Tissue harvesting Mice were transcardially perfused with PBS before tissue extraction. Either whole brains, spinal cords, or specific parts of the brain (cortex or cerebellum), not excluding meninges and choroid plexus, were collected, as indicated in the figure legends. Single-cell suspensions of tissues for all mice, excluding the Trem2 experiment, were achieved using software-controlled sealed homogenization system (Dispomix; http://www.biocellisolation.com) in PBS, followed by density gradient separation; Pellet was mixed with 40% percoll and centrifuged in 800G for 20 min at 12 C. Brains of Trem2 mice were processed as previously published (Wang et al., 2015) . Supernatant was discarded and pellet was taken further for antibody staining, as described below. Before staining, samples were blocked with Fc-block CD16/32 (BD Biosciences, San Jose, CA).
Single cell Sorting
Cell populations were sorted with SORP-aria (BD Biosciences, San Jose, CA). Prior to sorting, all samples were filtered through a 70-mm nylon mesh. For the sorting of whole immune cell populations, samples were gated for CD45 + (Brilliant-violet-421, 1:150, 30-F11, biolegend Inc. San Diego, CA), after exclusion of doublets. For the isolation of CD11c positive microglia, samples were gated positive for CD45, CD11b (APC CD11b, 1:100, M1/70, eBioscience or FITC CD11b, 1:100, M1/70, Biolegend Inc), and CD11c (Biotin CD11c, 1:100, N418, Biolegend Inc, followed by APC/Cy7 Streptavidin, 1:100, Biolegend Inc.), while excluding Gr-1 positive cells (PerCP Cy5.5, 1:100, RB6-8C5, eBioscience) and doublets. Isolated cells were single cell sorted into 384-well cell capture plates containing 2 mL of lysis solution and barcoded poly(T) reverse-transcription (RT) primers for single-cell RNA-seq . Four empty wells were kept in each 384-well plate as a no-cell control during data analysis. Immediately after sorting, each plate was spun down to ensure cell immersion into the lysis solution, snap frozen on dry ice, and stored at -80 C until processed. To record marker level of each single cell, the FACS Diva 7 ''index sorting'' function was activated during single cell sorting. Following the sequencing and analysis of the single cells, each surface marker was linked to the genome-wide expression profile. This methodology was used to optimize the gating strategy.
Massively Parallel Single-Cell RNA-seq Library preparation (MARS-seq) Single-cell libraries were prepared as previously described . In brief, mRNA from cell sorted into cell capture plates are barcoded and converted into cDNA and pooled using an automated pipeline. The pooled sample is then linearly amplified by T7 in vitro transcription, and the resulting RNA is fragmented and converted into a sequencing-ready library by tagging the samples with pool barcodes and illumina sequences during ligation, RT, and PCR. Each pool of cells was tested for library quality and concentration is assessed as described earlier .
Analysis of Single cell RNA-seq data MARS-seq libraries, pooled at equimolar concentrations, were sequenced using an Illumina NextSeq 500 sequencer, at a sequencing depth of 50K-100K reads per cell. Reads are condensed into original molecules by counting same unique molecular tags (UMI). We used statistics on empty-well spurious UMI detection to ensure that the batches we used for analysis showed a low level of cross-single-cell contamination (less than 3%).
MARS-seq reads were processed as previously described (Gury-BenAri et al., 2016) . Mapping of reads was done using HISAT (version 0.1.6) (Kim et al., 2015) ; reads with multiple mapping positions were excluded. Reads were associated with genes if they were mapped to an exon, using the UCSC genome browser for reference. Exons of different genes that shared genomic position on the same strand were considered a single gene with a concatenated gene symbol. Cells with less than 500 UMIs were discarded from the analysis. Genes with mean expression smaller than 0.005 UMIs/cell or with above average expression and low coefficient of variance (< 1.2) were also discarded. After filtering, cells contained a median of 2,373 unique molecules with 1,179 median genes per cell.
Graph-based clustering analysis
In order to assign cells to homogeneous clusters we used the PhenoGraph clustering algorithm (Levine et al., 2015) . Low-level processing of MARS-seq reads results in a matrix U with n rows and m columns, where rows represent genes and columns represent cells. Entry Uij contains the number of unique molecular identifiers (UMIs) from gene i that were found in cell j. PhenoGraph first builds a k-Nearest Neighbors (kNN) graph using the Euclidean distance (k = 30) and then refines this graph with the Jaccard similarity coefficient, where the edge weight between each two nodes is the number of neighbors they share divided by the total number of neighbors they have (Levine et al., 2015) . As input for PhenoGraph we first applied PCA of the expression matrix keeping the first 40 components. To partition the graph into modules/communities PhenoGraph uses the Louvain Method (Levine et al., 2015) . p values for differential expression analysis between different clusters were calculated using the Mann-Whitney U test (MATLAB R2016a ranksum function). Clusters annotation was done manually based on the expression of a large number of hallmark genes, for example, CD3 for T cells, S100A6 for granulocytes and Hexb, Cst3 and Cx3cr1 for microglia.
Graph projection
Graph is visualized in two dimensions using 'force-directed layout' (MATLAB R2016a graph plot function). Using attractive forces between adjacent nodes and repulsive forces between distant nodes.
Single cell clustering Heatmap view
For heatmap visualization of single cell clusters we selected the variable genes (rows) using a chi-square based assay. Cells were grouped according to their assignment to clusters, and the number of UMIs per gene in each cluster was compared against the expected number. Genes with p value passing a threshold of 1e-3 after a Bonferroni correction were selected for visualization. Values were log transformed and normalized to have mean expression of 1, genes were ordered using hierarchical clustering with correlation distance.
iChiP analysis
Reads were aligned to the mouse reference genome (mm9, NCBI 37) using Bowtie2 aligner version 2.2.5 with default parameters. The Picard tool MarkDuplicates from the Broad Institute (http://broadinstitute.github.io/picard/) was used to remove PCR duplicates. For scatterplot, the read density (number of reads in 10 million total reads per 1000 bp) was calculated using a sliding window across the entire genome of with 500bp overlap. The region intensity was given in log-base2 of the normalized density (log2(x+1)).
Comparing DAM program in AD, ALS and aging To compare the DAM expression profile between various neurodegenerative conditions we used correlation between the average expression profiles of the DAM cluster in each condition including all genes with at least 0.1 molecules per cell in any condition (r > 0.9 for pairwise correlations). In addition, we have searched for differential genes using the non-parametric Mann-Whitney U test comparing the two clusters and did not find significant changes of the DAM program between the different conditions.
Analysis of Trem2 single cell data Trem2 experiment (related to Figure 5 ) was performed using a different cell processing protocol (Wang et al., 2015) ; we therefore detected an increase in the expression of stress related genes, such as Fos, Jun, Junb, Klf6, as well as some inflammatory genes, such as Nfkbiz, Tnf, Tnfaip3. This stress / inflammation pattern was not consistent between WT or AD mice and was observed in both samples in different levels, stronger in the WT Trem2+/+ sample. As these genes were not expressed in our previous datasets, we assume they are an artifact of the tissue processing protocol. To exclude this potential source of variability we performed the Trem2 analysis using the same gene sets used in the time course experiment. The stress / inflammation related genes are indicated in red in Table S7 .
QUANTIFICATION AND STATISTICAL ANALYSIS
p values for differential expression analysis between different clusters were calculated using the Mann-Whitney U test (MATLAB R2016a ranksum function), comparing molecular count in single cells from each group using a non-parametric statistical test.
Quantification of immunofluorescence imaging (over 900 cells) as well as single molecule FISH analysis (over 100 cells) was done using the Mann-Whitney U test (MATLAB R2016a ranksum function).
DATA AND SOFTWARE AVAILABILITY
The accession number for the sequencing data reported in this paper is GEO: GSE98971. This parent directory includes the following 
